GlassScriptPhysician profile
Winston Ortiz
NPI 1134196215
$59,828.86
in general payments reported to CMS, 2019-2025
68 companies · $4,378 in 2025
The $4,378 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $12K · 2021: $18K · 2022: $2,963 · 2023: $3,352 · 2024: $3,765 · 2025: $4,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $320 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,025.32 |
| Education | $319.78 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $12,354.11 | 2019-2025 | Mavenclad |
| Allergan, INC. | $10,442.76 | 2019-2021 | |
| Abbvie INC. | $9,102.77 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $5,844.43 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Greenwich Biosciences, INC. | $3,687.89 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $1,322.39 | 2019-2025 | Ultomiris, Soliris |
| Jazz Pharmaceuticals INC. | $1,273.58 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,187.36 | 2019-2025 | |
| Sk Life Science, INC. | $1,103.70 | 2020-2025 | |
| Lilly USA, LLC | $1,007.45 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Biogen, INC. | $948.05 | 2019-2025 | Tysabri, Skyclarys, Tysabri |
| Ucb, INC. | $923.21 | 2020-2025 | Fintepla, Nayzilam, Zilbrysq |
| Amgen INC. | $868.66 | 2019-2025 | Uplizna, Aimovig |
| Tg Therapeutics, INC. | $797.16 | 2023-2025 | |
| Eisai INC. | $767.11 | 2019-2025 |
Show all 67 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Winston Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.